혈장 분획 시장 : 산업 규모, 점유율, 동향, 기회, 예측 - 제품별, 방법별, 용도별, 최종 용도별, 지역별 및 경쟁(2021-2031년)

The global blood plasma fractionation market is projected to expand significantly, from USD 37.11 billion in 2025 to USD 60.85 billion by 2031, demonstrating an 8.59% compound annual growth rate. This market centers on the industrial separation of human blood plasma into vital therapeutic proteins like immunoglobulins, albumin, and coagulation factors. Its growth is largely fueled by the increasing worldwide incidence of immunodeficiency disorders and a growing elderly population in need of critical care treatments. Moreover, enhanced diagnostic technologies are boosting the detection rates of rare diseases, consequently escalating the clinical demand for plasma-derived medicinal products beyond their conventional applications.

However, despite this strong demand, the market is challenged by intricate logistics and the high expenses involved in obtaining raw materials. A major obstacle is the heavy dependence on a few regions for plasma collection, which exposes the supply chain to vulnerabilities, as North American donors alone are expected to provide over 63% of the global supply by 2025, according to the Plasma Protein Therapeutics Association. This geographical concentration underscores the difficulty in establishing diverse collection sources to maintain a stable and adequate worldwide inventory of fractionation substrates.

Market Driver

A primary catalyst for the market is the surging demand for immunoglobulins within neurology and immunology, fueled by their growing clinical utility in treating conditions like Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Primary Immunodeficiency (PID). As diagnostic rates improve and off-label applications become more common, manufacturers are experiencing significant revenue growth in their immunology product lines, leading to a need for increased production to meet ongoing patient requirements. This strong consumption trend directly impacts corporate financial performance and reinforces the industry's focus on plasma-derived medicinal products, as evidenced by CSL Limited's August 2024 annual report, which noted a 20% rise in immunoglobulin product sales to $5.66 billion, underscoring this therapeutic class's major contribution to market expansion.

Supporting this growth trajectory, the rapid expansion of plasma collection and fractionation infrastructure is another crucial driver, with major industry participants actively boosting donor center capacity and improving purification efficiencies. This strategic enlargement of the collection network is vital for reducing supply chain vulnerabilities and decreasing the cost per liter of source plasma. As a result, higher collection volumes are stabilizing the global supply chain and allowing manufacturers to fulfill increasing orders. For example, Grifols reported an 8% increase in plasma supply in its May 2024 First Quarter Results, demonstrating the effectiveness of these operational efforts. The overall market resilience is further highlighted by sector revenues; Grifols' total revenue for the first half of 2024 reached EUR 3,444 million.

Market Challenge

A significant logistical bottleneck that impedes the growth of the Global Blood Plasma Fractionation Market stems from its heavy reliance on a limited number of regions for plasma collection. This geographical imbalance necessitates the industry to manage costly and intricate transcontinental supply chains for transporting biological raw materials from donor-abundant countries to fractionation facilities globally. Consequently, manufacturers frequently encounter feedstock shortages, which hinder their ability to scale production volumes to meet the rising clinical demand for immunoglobulin and coagulation therapies.

This inherent supply chain vulnerability directly causes market stagnation in regions dependent on imports, where the inability to secure adequate fractionation substrates results in critical shortages of essential therapies. Such limitations on availability effectively restrict revenue potential and impede market penetration into underserved areas. For instance, the European Blood Alliance reported in 2024 that ongoing supply constraints and import dependencies prompted the European Medicines Agency to foresee shortages of crucial plasma-derived medicinal products in 14 European nations. These disruptions clearly demonstrate how challenges in diversifying collection sources directly limit the industry's capacity to capitalize on increasing global demand.

Market Trends

The market is experiencing a fundamental transformation driven by the increasing adoption of subcutaneous immunoglobulin (SCIg) administration, largely due to a rising patient preference for home-based therapies that reduce reliance on clinical settings. This method enables self-administration and ensures consistent serum antibody levels, thereby effectively reducing the systemic side effects often linked with intravenous treatments. In response, manufacturers are introducing high-concentration formulations and intuitive devices specifically designed to support this independent treatment model. This rapid shift is supported by corporate results; Grifols, in its July 2024 'First Half 2024 Results', reported a 60% surge in sales of its subcutaneous product Xembify at constant currency, highlighting the strong commercial traction of this therapeutic approach.

Concurrently, the localization of fractionation facilities is emerging as a crucial strategy for countries aiming to achieve self-sufficiency and protect their healthcare systems from global supply fluctuations. Regions that traditionally rely on imports are evolving beyond basic procurement models to establish their own domestic processing infrastructure. This allows for the conversion of locally collected plasma into finished medicinal products within national boundaries. This structural change seeks to secure an independent supply of essential proteins while minimizing risks associated with international logistics. An example of this trend is the Indonesia Investment Authority's November 2024 announcement of a joint venture for constructing a domestic fractionation plant, intended to process 600,000 liters annually to meet national demand.

Key Market Players

• Grifols, S.A.
• CSL Limited
• Takeda Pharmaceutical Company Limited
• Octapharma AG
• Kedrion S.p.A
• Biotest AG
• Bio Products Laboratory Ltd.
• Intas Pharmaceuticals Ltd.
• ADMA Biologics, Inc.
• Meiji Holdings Co., Ltd.

Report Scope

In this report, the Global Blood Plasma Fractionation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Blood Plasma Fractionation Market, By Product

• Albumin
• Immunoglobulins
• Coagulation Factors
• Protease Inhibitors
• Others

Blood Plasma Fractionation Market, By Method

• Centrifugation
• Depth Filtration
• Chromatography
• Others

Blood Plasma Fractionation Market, By Application

• Neurology
• Haematology
• Oncology
• Immunology
• Pulmonology
• Others

Blood Plasma Fractionation Market, By End Use

• Hospitals & Clinics
• Clinical Research
• Others

Blood Plasma Fractionation Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Blood Plasma Fractionation Market.

Available Customizations:

Global Blood Plasma Fractionation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Blood Plasma Fractionation Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Albumin, Immunoglobulins, Coagulation Factors, Protease Inhibitors, Others)
  • 5.2.2. By Method (Centrifugation, Depth Filtration, Chromatography, Others)
  • 5.2.3. By Application (Neurology, Haematology, Oncology, Immunology, Pulmonology, Others)
  • 5.2.4. By End Use (Hospitals & Clinics, Clinical Research, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Blood Plasma Fractionation Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Method
  • 6.2.3. By Application
  • 6.2.4. By End Use
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Blood Plasma Fractionation Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Method
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End Use
  • 6.3.2. Canada Blood Plasma Fractionation Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Method
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End Use
  • 6.3.3. Mexico Blood Plasma Fractionation Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Method
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End Use

7. Europe Blood Plasma Fractionation Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Method
  • 7.2.3. By Application
  • 7.2.4. By End Use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Blood Plasma Fractionation Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Method
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End Use
  • 7.3.2. France Blood Plasma Fractionation Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Method
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End Use
  • 7.3.3. United Kingdom Blood Plasma Fractionation Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Method
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End Use
  • 7.3.4. Italy Blood Plasma Fractionation Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Method
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End Use
  • 7.3.5. Spain Blood Plasma Fractionation Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Method
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End Use

8. Asia Pacific Blood Plasma Fractionation Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Method
  • 8.2.3. By Application
  • 8.2.4. By End Use
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Blood Plasma Fractionation Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Method
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End Use
  • 8.3.2. India Blood Plasma Fractionation Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Method
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End Use
  • 8.3.3. Japan Blood Plasma Fractionation Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Method
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End Use
  • 8.3.4. South Korea Blood Plasma Fractionation Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Method
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End Use
  • 8.3.5. Australia Blood Plasma Fractionation Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Method
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End Use

9. Middle East & Africa Blood Plasma Fractionation Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Method
  • 9.2.3. By Application
  • 9.2.4. By End Use
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Blood Plasma Fractionation Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Method
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End Use
  • 9.3.2. UAE Blood Plasma Fractionation Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Method
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End Use
  • 9.3.3. South Africa Blood Plasma Fractionation Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Method
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End Use

10. South America Blood Plasma Fractionation Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Method
  • 10.2.3. By Application
  • 10.2.4. By End Use
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Blood Plasma Fractionation Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Method
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End Use
  • 10.3.2. Colombia Blood Plasma Fractionation Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Method
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End Use
  • 10.3.3. Argentina Blood Plasma Fractionation Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Method
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Blood Plasma Fractionation Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Grifols, S.A.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. CSL Limited
• 15.3. Takeda Pharmaceutical Company Limited
• 15.4. Octapharma AG
• 15.5. Kedrion S.p.A
• 15.6. Biotest AG
• 15.7. Bio Products Laboratory Ltd.
• 15.8. Intas Pharmaceuticals Ltd.
• 15.9. ADMA Biologics, Inc.
• 15.10. Meiji Holdings Co., Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer